

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

UPDATED INFORMATION OF THE GROUP'S PRODUCTS - INSULIN DEGLUDEC AND INSULIN ASPART INJECTION

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

The board of directors (the "Board") of the Company is pleased to announce that on 15 April 2022, The United Bio-Technology (Hengqin) Co., Ltd. ("The United Bio-Technology"), a wholly-owned subsidiary of the Company, received the Notice on Acceptance of Clinical Trial Registration (Reference No.: CXSL2200172) issued by the National Medical Products Administration regarding the insulin degludec and insulin aspart injection.

Insulin degludec and insulin aspart injection is a new-generation ultra-long-acting combination of basal insulin analogue and mealtime insulin analogue, containing 70% insulin degludec and 30% insulin aspart. The two components are soluble independently and reliably, without changes of their respective pharmacological properties, and work together to control the fasting blood glucose and the postprandial blood glucose. Compared with the premixed insulin analogues applied clinically, insulin degludec and insulin aspart injection demonstrates a better simulation of the secretion pattern of physiological insulin and delivers a safer and more effective treatment for reducing blood glucose, thus providing diabetes patients with a better option to comprehensively control blood glucose.

The United Bio-Technology, a wholly-owned subsidiary of the Company, founded in May 2021 and located at the Guangdong-Macau Traditional Chinese Medicine Industry Park, Hengqin, Zhuhai, Guangdong Province, is now in operation. The United Bio-Technology will promote the development of innovative biological drugs that are about to enter the clinical trial phases and focus on the development of new drugs with independent intellectual property and innovative generic drugs with strong competitiveness. In the future, The United Bio-Technology will strengthen international cooperation and project introduction, and promote the development of new drugs and the capital operation, aiming to help the Company to achieve leapfrog development in the biomedical field and build the first-of-class biomedical research and development and service platform in China.

As the second enterprise in China to apply for the clinical trial of insulin degludec and insulin aspart injection, the Company achieves another breakthrough in the research and development of diabetes drugs. In the future, the Company will continue to commit itself to the research and development of new products, and focus on enhancing its competitiveness and creativity in the biopharmaceutical industry, with a view of creating greater benefits for the Company and its shareholders.

By Order of the Board
The United Laboratories International Holdings Limited
Tsoi Hoi Shan
Chairman

Hong Kong, 26 April 2022

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Ms. Fu Xiao Nan as independent non-executive directors.